Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
Berlin, May 16, 2023 – Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). This news follows asundexian’s first U.S…Read More
K.E.D. Coan
September 15, 2023